SLC25A47 and metabolic dysfunction-associated steatohepatitis: In this study, we found alleviation of NASH in both in vivo and in vitro levels after RNA interference (Figs 3 and 4), supporting the potential therapeutic effect of antagonizing HDMCP in NASH.